Current Licensing
Opportunities
Curated deals available through the BioRich International network. Request details on any opportunity — our team will follow up within 1–2 business days.
HER2-targeted ADC
Novel HER2-targeted antibody-drug conjugate with differentiated linker-payload technology. Phase I dose-escalation complete; favorable tolerability profile demonstrated in first two cohorts.
Oral GLP-1 Receptor Agonist
Once-daily oral GLP-1 receptor agonist in Phase II for type 2 diabetes and obesity. Strong Phase I PK/PD data. Seeking North American commercialization partner.
Enzyme Replacement Therapy
Recombinant enzyme replacement therapy for lysosomal storage disorder. Phase II completed with statistically significant primary endpoint. Regulatory path to NDA/BLA well defined.
IL-17A/F Bispecific Antibody
Bispecific antibody co-targeting IL-17A and IL-17F for moderate-to-severe psoriasis and psoriatic arthritis. Phase I safety and tolerability data available.
4th Generation CAR-T
Next-generation armored CAR-T cell therapy for relapsed/refractory multiple myeloma. Phase I/II enrollment ongoing; early efficacy signals reported.
NLRP3 Inflammasome Inhibitor
Selective NLRP3 inflammasome inhibitor with brain-penetrant properties. In vivo efficacy in Alzheimer's and Parkinson's disease models. Seeking IND-enabling study partner or full licensee.
KRAS G12C Inhibitor
Chinese pharmaceutical company seeking in-licensing rights for an approved or Phase III KRAS G12C inhibitor for the China market. Strong commercial infrastructure; full regulatory support.
PCSK9 Monoclonal Antibody
Established Chinese cardiovascular specialty company seeking in-licensing rights to an approved or late-stage PCSK9 inhibitor. Proven commercial team in tier 1 and tier 2 cities.
Don't see what you're looking for? We have additional opportunities not listed publicly.
Discuss your criteria with our team